• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 115 -3 (77) 2025 - Zhumaboeva M.U., Babaev K.T. - ASSOCIATION OF SOD2 GENE RS11575993 (C60T) POLYMORPHISM WITH THE DEVELOPMENT OF MYELOPROLIFERATIVE NEOPLASIA IN KHOREZM REGION

115 -3 (77) 2025 - Zhumaboeva M.U., Babaev K.T. - ASSOCIATION OF SOD2 GENE RS11575993 (C60T) POLYMORPHISM WITH THE DEVELOPMENT OF MYELOPROLIFERATIVE NEOPLASIA IN KHOREZM REGION

ASSOCIATION OF SOD2 GENE RS11575993 (C60T) POLYMORPHISM WITH THE DEVELOPMENT OF MYELOPROLIFERATIVE NEOPLASIA IN KHOREZM REGION

Zhumaboeva M.U. - Khorezm regional multidisciplinary medical center Uzbekistan

Babaev K.T. - Republican Specialized Scientific and Practical Medical Hematology Center

Jumanazarova Sh.R. - Tashkent Medical Academy

Resume

Myeloproliferative neoplasias (MPNs) are a group of clonal hematologic diseases characterized by unregulated proliferation of one or more myeloid lineages of hematopoietic cells. In recent decades, scientific interest in the molecular-genetic mechanisms of development of this pathology has increased significantly, especially in the context of regional population peculiarities. Khorezm region, as a unique geographical and ethnic region of Uzbekistan, creates special conditions for studying genetic features of myeloproliferative neoplasia. The SuperOxide Dismutase 2 (SOD2) gene encoding manganese-dependent superoxide dismutase plays a critical role in the regulation of oxidative stress and protection of cells from the damaging effects of reactive oxygen species.

Keywords: MPN, polymorphism, rs11575993, SOD2 gene.

First page

650

Last page

656

For citation:Zhumaboeva M.U., Babaev K.T., Jumanazarova Sh.R. - ASSOCIATION OF SOD2 GENE RS11575993 (C60T) POLYMORPHISM WITH THE DEVELOPMENT OF MYELOPROLIFERATIVE NEOPLASIA IN KHOREZM REGION//New Day in Medicine 3(77)2025 650-656 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Poluben LO, Neumerzhytska LV, Klymenko SV, Fraenkel P, Balk C, Shumeiko OO. Molecular genetic abnormalities in the genome of patients with ph-negative myeloproliferative neoplasia affected by ionizing radiation as a result of the chornobyl nuclear accident. Probl Radiac Med Radiobiol. 2020 Dec; 25:362-373.
  2. Rolles B, Mullally A. Molecular Pathogenesis of Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2022 Dec; 17(6):319-329. doi: 10.1007/s11899-022-00685-1. Epub 2022 Nov 7. PMID: 36336766.
  3. Constantinescu SN, Vainchenker W, Levy G, Papadopoulos N. Functional Consequences of Mutations in Myeloproliferative Neoplasms. Hemasphere. 2021 Jun 1; 5(6):e578.
  4. Bellanné-Chantelot C, Rabadan Moraes G, Schmaltz-Panneau B, Marty C, Vainchenker W, Plo I. Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. Blood Rev. 2020 Jul; 42:100710. doi: 10.1016/j.blre.2020.100710. Epub 2020 May 29. PMID: 32532454.
  5. Lim J, Ross DM, Brown AL, Scott HS, Hahn CN. Germline genetic variants that predispose to myeloproliferative neoplasms and hereditary myeloproliferative phenotypes. Leuk Res. 2024 Nov; 146:107566. doi: 10.1016/j.leukres.2024.107566. Epub 2024 Aug 25. PMID: 39316992.
  6. Braunstein EM, Imada E, Pasca S, Wang S, Chen H, Alba C, Hupalo DN, Wilkerson M, Dalgard CL, Ghannam J, Liu Y, Marchionni L, Moliterno A, Hourigan CS, Gondek LP. Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms. Leukemia. 2023 Mar; 37(3):627-635. doi: 10.1038/s41375-022-01797-6. Epub 2022 Dec 21. PMID: 36543879.
  7. Rumi E, Cazzola M. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. Br J Haematol. 2017 Sep; 178(5):689-698. doi: 10.1111/bjh.14713. Epub 2017 Apr 25. PMID: 28444727.
  8. Takenaka K. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies]. Rinsho Ketsueki. 2016;57(10):1944-1955. Japanese. doi: 10.11406/rinketsu.57.1944. PMID: 27725592.
  9. Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur-Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. Biochem Biophys Res Commun. 2018 Apr 15; 498(4):715-722. doi: 10.1016/j.bbrc.2018.03.023. Epub 2018 Mar 17. PMID: 29550484.
  10. Song J, Huang C, Jia L, Wang M, Wu C, Ji X, Song H, Meng R, Zhou D. Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review. BMC Neurol. 2024 Oct 12; 24(1):386.
  11. Arber DA et all. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15; 140(11):1200-1228. doi: 10.1182/blood.2022015850. PMID: 35767897; PMCID: PMC9479031.

    file

    download